miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

Journal Article (Journal Article)

High BAALC expression levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) patients. Recently, miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151 expression levels and to gain insight into the biologic and prognostic interplay between miR-3151 and its host, miR-3151 and BAALC expression were measured in pretreatment blood of 179 CN-AML patients. Gene-expression profiling and miRNA-expression profiling were performed using microarrays. High miR-3151 expression was associated with shorter disease-free and overall survival, whereas high BAALC expression predicted failure of complete remission and shorter overall survival. Patients exhibiting high expression of both miR-3151 and BAALC had worse outcome than patients expressing low levels of either gene or both genes. In gene-expression profiling, high miR-3151 expressers showed down-regulation of genes involved in transcriptional regulation, posttranslational modification, and cancer pathways. Two genes, FBXL20 and USP40, were validated as direct miR-3151 targets. The results of the present study show that high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and affects different outcome end points than its host gene, BAALC. The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications.

Full Text

Duke Authors

Cited Authors

  • Eisfeld, A-K; Marcucci, G; Maharry, K; Schwind, S; Radmacher, MD; Nicolet, D; Becker, H; Mrózek, K; Whitman, SP; Metzeler, KH; Mendler, JH; Wu, Y-Z; Liyanarachchi, S; Patel, R; Baer, MR; Powell, BL; Carter, TH; Moore, JO; Kolitz, JE; Wetzler, M; Caligiuri, MA; Larson, RA; Tanner, SM; de la Chapelle, A; Bloomfield, CD

Published Date

  • July 12, 2012

Published In

Volume / Issue

  • 120 / 2

Start / End Page

  • 249 - 258

PubMed ID

  • 22529287

Pubmed Central ID

  • PMC3398762

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2012-02-408492


  • eng

Conference Location

  • United States